<?xml version='1.0' encoding='utf-8'?>
<document id="21223356"><sentence text="Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men."><entity charOffset="58-69" id="DDI-PubMed.21223356.s1.e0" text="risperidone" /></sentence><sentence text="• Several lines of evidence suggest a possible role of 5-HT(6) receptor antagonists in dementia or cognitive dysfunction of schizophrenia" /><sentence text=" SB-742457 is a potent 5-HT(6) antagonist and has shown efficacy in different animal models of cognitive impairment" /><sentence text=" It is currently in development as a cognitive enhancer" /><sentence text=" Risperidone, commonly used to control agitation and psychotic features in both schizophrenia and Alzheimer's disease, is a D(2)/5-HT(2A ) antagonist with low affinity for 5-HT(6) receptors and limited effects on cognitive parameters"><entity charOffset="1-12" id="DDI-PubMed.21223356.s5.e0" text="Risperidone" /></sentence><sentence text="" /><sentence text="• As the combination of risperidone and SB-742457 may constitute a reasonable combination in cognitively impaired patients, pharmacodynamic interaction effects were investigated in this study"><entity charOffset="24-35" id="DDI-PubMed.21223356.s7.e0" text="risperidone" /><entity charOffset="40-49" id="DDI-PubMed.21223356.s7.e1" text="SB-742457" /><pair ddi="false" e1="DDI-PubMed.21223356.s7.e0" e2="DDI-PubMed.21223356.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s7.e0" e2="DDI-PubMed.21223356.s7.e1" /></sentence><sentence text=" The only significant drug-drug interaction was a small increase of electroencephalogram (EEG) alpha and beta bands, which might suggest mild arousing activity of SB-742457 on the central nervous system-depressant effects of risperidone"><entity charOffset="163-172" id="DDI-PubMed.21223356.s8.e0" text="SB-742457" /><entity charOffset="225-236" id="DDI-PubMed.21223356.s8.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.21223356.s8.e0" e2="DDI-PubMed.21223356.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s8.e0" e2="DDI-PubMed.21223356.s8.e1" /></sentence><sentence text=" The clinical relevance of these findings in patients remains to be established" /><sentence text=" Additionally, this study provided an extensive multidimensional pharmacodynamic profile of risperidone in healthy volunteers, showing that this antipsychotic suppresses motor performance (eye-hand coordination, finger tapping and postural stability), alertness, memory and neurophysiological functions (saccadic eye movements and EEG power spectrum)"><entity charOffset="92-103" id="DDI-PubMed.21223356.s10.e0" text="risperidone" /></sentence><sentence text="" /><sentence text="Several lines of evidence suggest a possible role of 5-HT(6 ) receptor antagonists in cognitive dysfunction of schizophrenia" /><sentence text=" Atypical antipsychotics, such as risperidone, are currently used in these disorders"><entity charOffset="34-45" id="DDI-PubMed.21223356.s13.e0" text="risperidone" /></sentence><sentence text=" Therefore, the pharmacological interactions between the 5-HT(6) antagonist SB-742457 and risperidone were investigated in the light of possible co-medication"><entity charOffset="76-85" id="DDI-PubMed.21223356.s14.e0" text="SB-742457" /><entity charOffset="90-101" id="DDI-PubMed.21223356.s14.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.21223356.s14.e0" e2="DDI-PubMed.21223356.s14.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s14.e0" e2="DDI-PubMed.21223356.s14.e1" /></sentence><sentence text="" /><sentence text="A randomized, double-blind, two-way crossover design was used to study the interaction between multiple doses SB-742457 50 mg and a single dose risperidone 2 mg in 18 healthy subjects"><entity charOffset="110-119" id="DDI-PubMed.21223356.s16.e0" text="SB-742457" /><entity charOffset="144-155" id="DDI-PubMed.21223356.s16.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.21223356.s16.e0" e2="DDI-PubMed.21223356.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s16.e0" e2="DDI-PubMed.21223356.s16.e1" /></sentence><sentence text="" /><sentence text="Treatment was well tolerated" /><sentence text=" The most common adverse event was somnolence in 83% during the combination vs" /><sentence text=" 50% of subjects after risperidone, 32% after placebo and 11% after SB-742457"><entity charOffset="23-34" id="DDI-PubMed.21223356.s20.e0" text="risperidone" /><entity charOffset="68-77" id="DDI-PubMed.21223356.s20.e1" text="SB-742457" /><pair ddi="false" e1="DDI-PubMed.21223356.s20.e0" e2="DDI-PubMed.21223356.s20.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s20.e0" e2="DDI-PubMed.21223356.s20.e1" /></sentence><sentence text=" Combination treatment produced a statistically significant increase in the maximum plasma concentration of risperidone and had no effect on SB-742457 pharmacokinetics"><entity charOffset="108-119" id="DDI-PubMed.21223356.s21.e0" text="risperidone" /><entity charOffset="141-150" id="DDI-PubMed.21223356.s21.e1" text="SB-742457" /><pair ddi="false" e1="DDI-PubMed.21223356.s21.e0" e2="DDI-PubMed.21223356.s21.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s21.e0" e2="DDI-PubMed.21223356.s21.e1" /></sentence><sentence text=" Risperidone decreased saccadic peak velocity, finger tapping, adaptive tracking, subjective alertness, delayed word recognition and body sway and increased electroencephalogram (EEG) theta power and prolactin"><entity charOffset="1-12" id="DDI-PubMed.21223356.s22.e0" text="Risperidone" /></sentence><sentence text=" The only pharmacodynamic interaction of risperidone and SB-742457 was an increase of absolute EEG alpha (ratio = 1"><entity charOffset="41-52" id="DDI-PubMed.21223356.s23.e0" text="risperidone" /><entity charOffset="57-66" id="DDI-PubMed.21223356.s23.e1" text="SB-742457" /><pair ddi="false" e1="DDI-PubMed.21223356.s23.e0" e2="DDI-PubMed.21223356.s23.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s23.e0" e2="DDI-PubMed.21223356.s23.e1" /></sentence><sentence text="25, 95% CI = 1" /><sentence text="11, 1" /><sentence text="40, P= 0" /><sentence text="0004) and beta power (ratio = 1" /><sentence text="14, 95% CI = 1" /><sentence text="03, 1" /><sentence text="27, P= 0" /><sentence text="016)" /><sentence text=" No significant effects of SB-742457 alone were found"><entity charOffset="27-36" id="DDI-PubMed.21223356.s32.e0" text="SB-742457" /></sentence><sentence text="" /><sentence text="The pharmacokinetic interactions between SB-742457 and risperidone detected in this study were not clinically relevant"><entity charOffset="41-50" id="DDI-PubMed.21223356.s34.e0" text="SB-742457" /><entity charOffset="55-66" id="DDI-PubMed.21223356.s34.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.21223356.s34.e0" e2="DDI-PubMed.21223356.s34.e0" /><pair ddi="false" e1="DDI-PubMed.21223356.s34.e0" e2="DDI-PubMed.21223356.s34.e1" /></sentence><sentence text=" The increase in EEG alpha and beta power is incompatible with enhanced risperidone activity, but could point to mild arousing effects of the combination"><entity charOffset="72-83" id="DDI-PubMed.21223356.s35.e0" text="risperidone" /></sentence><sentence text=" Most pharmacodynamic changes of risperidone are consistent with previously reported data"><entity charOffset="33-44" id="DDI-PubMed.21223356.s36.e0" text="risperidone" /></sentence><sentence text=" The potential cognitive effects of SB-742457 remain to be established"><entity charOffset="36-45" id="DDI-PubMed.21223356.s37.e0" text="SB-742457" /></sentence><sentence text="" /></document>